Andere Sprachen TELA Bio, Inc.

Aktien

A2PUP9

US8723811084

TELA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
4.7 ^USD	-8.56%		-13.60%	-29.00%

04.06.	TELA Bio, Inc. ernennt Jeffrey Blizard zum Mitglied des Vorstands	CI
20.05.	TELA Bio, Inc. ernennt Greg Firestone zum Chief Commercial Officer	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

TELA Bio Appoints Jeffrey Blizard to its Board of Directors	04.06.
TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors	04.06.
TELA Bio Appoints Greg Firestone as Chief Commercial Officer	20.05.
TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer	20.05.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	10.05.
Earnings Flash (TELA) TELA BIO Posts Q1 Revenue $16.6M, vs. Street Est of $16.3M	09.05.
TELA Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
TELA Bio Reports First Quarter 2024 Financial Results	09.05.
TELA Bio, Inc. Provides Revenue Guidance for the Year 2024	09.05.
Morgans rates ARX as Add	01.05.
TELA Bio to Announce First Quarter 2024 Financial Results	25.04.
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR, Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures	16.04.
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures	15.04.
TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR	15.04.
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy	08.04.
Earnings Flash (TELA) TELA BIO Reports Q4 Revenue $17M, vs. Street Est of $16.4M	21.03.
TELA Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21.03.
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results	21.03.
TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2024	21.03.
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery	21.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen TELA Bio, Inc.

Aktien

A2PUP9

US8723811084

TELA

Andere Sprachen

Filter